Please use this identifier to cite or link to this item:
|Title:||Development and implementation of the MammaPrint® Algorithm (MPA) to reduce chemotherapy overtreatment in South African patients with early stage breast cancer||Authors:||Grant, KA
De Klerk, M
Kotze, Maritha J.
|Keywords:||MammaPrint® algorithm (MPA);chemotherapy overtreatment;South African patients;breast cancer;Histopathology||Issue Date:||2012||Publisher:||Wiley||Source:||Grant, K. A., Apffelstaedt, J. P., Wright, C. et al. 2012. Development and implementation of the MammaPrint® Algorithm (MPA) to reduce chemotherapy overtreatment in South African patients with early stage breast cancer. Histopathology, 61(1): 20-21. [https://onlinelibrary.wiley.com/toc/13652559/2012/61/s1]||Journal:||Histopathology||Abstract:||Compared to conventional risk assessment models, transcriptional profiling may reduce prescription of chemotherapy in patients with early-stage breast cancer by approximately one-third. This significant reduction prompted a South African medical insurer to subject the 70-gene MammaPrint® (MP) test to a Health Technology Assessment (HTA) in 2009. The HTA introduced a set of test eligibility criteria – the MammaPrint® Algorithm (MPA). This translational research study was undertaken to determine whether the MPA based partly on immunohistochemical Estrogen Receptor (ER) and HER2 status is appropriate for use in routine clinical practice||URI:||https://onlinelibrary.wiley.com/toc/13652559/2012/61/s1
|Appears in Collections:||HWSci - Journal Articles (DHET subsidised)|
Show full item record
Files in This Item:
|Development and implementation of the MammaPrint.pdf||Article||131.69 kB||Adobe PDF||View/Open|
Items in Digital Knowledge are protected by copyright, with all rights reserved, unless otherwise indicated.